187 related articles for article (PubMed ID: 36712341)
1. Intratumoral nanobody-IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice.
Lutz EA; Jailkhani N; Momin N; Huang Y; Sheen A; Kang BH; Wittrup KD; Hynes RO
PNAS Nexus; 2022 Nov; 1(5):pgac244. PubMed ID: 36712341
[TBL] [Abstract][Full Text] [Related]
2. Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy.
Jung K; Yoo S; Kim JE; Kim W; Kim YS
Front Immunol; 2022; 13():1034774. PubMed ID: 36405748
[TBL] [Abstract][Full Text] [Related]
3. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
4. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
5. Immunocytokines are a promising immunotherapeutic approach against glioblastoma.
Weiss T; Puca E; Silginer M; Hemmerle T; Pazahr S; Bink A; Weller M; Neri D; Roth P
Sci Transl Med; 2020 Oct; 12(564):. PubMed ID: 33028706
[TBL] [Abstract][Full Text] [Related]
6. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
Kaspar M; Trachsel E; Neri D
Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
[TBL] [Abstract][Full Text] [Related]
7. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
8. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
9. Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors.
Mortensen MR; Mock J; Bertolini M; Stringhini M; Catalano M; Neri D
Oncotarget; 2020 Nov; 11(44):3972-3983. PubMed ID: 33216834
[TBL] [Abstract][Full Text] [Related]
10. The present and future of immunocytokines for cancer treatment.
Gout DY; Groen LS; van Egmond M
Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
[TBL] [Abstract][Full Text] [Related]
11. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
[TBL] [Abstract][Full Text] [Related]
12. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.
Tzeng A; Kwan BH; Opel CF; Navaratna T; Wittrup KD
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3320-5. PubMed ID: 25733854
[TBL] [Abstract][Full Text] [Related]
13. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice.
Puca E; De Luca R; Seehusen F; Rodriguez JMM; Neri D
J Control Release; 2020 Jan; 317():282-290. PubMed ID: 31790729
[TBL] [Abstract][Full Text] [Related]
15. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
16. A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties
Ongaro T; Gouyou B; Stringhini M; Corbellari R; Neri D; Villa A
Oncotarget; 2020 Oct; 11(41):3698-3711. PubMed ID: 33110477
[TBL] [Abstract][Full Text] [Related]
17. Immunocytokines: a promising approach to cancer immunotherapy.
Lode HN; Xiang R; Becker JC; Gillies SD; Reisfeld RA
Pharmacol Ther; 1998 Dec; 80(3):277-92. PubMed ID: 9888698
[TBL] [Abstract][Full Text] [Related]
18. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
19. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
Hemmerle T; Neri D
Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
[TBL] [Abstract][Full Text] [Related]
20. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
